Advocacy Resources

Laboratory Developed Testing Procedures (LDPs)

Molecular pathology professionals dedicate their careers to ensuring that patients receive the most appropriate services for their clinical conditions, and that all laboratory developed testing procedures (LDPs) are accurate, precise, clinically relevant, and continually monitored for quality performance. AMP closely monitors and influences public policy affecting LDPs oversight. AMP has numerous resources on this issue freely available to the public, including efforts to modernize the Clinical Laboratory Improvement Amendments (CLIA) program at the Centers for Medicare &Medicaid Services (CMS).



Coverage and Reimbursement

The final rule implementing section 216 of the Protecting Access to Medicare Act (PAMA) was released in June 2016. With an implementation date of January 1, 2018, PAMA significantly revises the Medicare payment system for clinical diagnostic laboratory tests by requiring that Medicare payment for clinical laboratories be based on the weighted median of private payer rates along with a number of other provisions. AMP is helping to prepare clinical laboratories for PAMA by offering resources that provide details on the data reporting requirements as well as other provisions included in PAMA.

Corporate Partners